Category - Developments

Developments

Clinigence, Nutex Health complete merger; listing on NASDAQ

Clinigence Holdings (OTC:CLNH) and Nutex Health Holdco completed their business combination. The newly combined company, which will continue under the new name, Nutex Health, brings together two complementary...

April 1, 2022

Developments

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Palisade Bio (NASDAQ:PALI) received a “study may proceed” letter from the FDA for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing...

March 22, 2022

Developments

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Closely-held Cytovale announced that a new study of its investigational IntelliSep test has been published in the peer-reviewed journal, PLOS ONE. The study demonstrated that the IntelliSep test has the potential to...

March 17, 2022

Developments

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

Immunomic Therapeutics plans to start a Phase 1 clinical study of a plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer, using PharmaJet’s...

March 15, 2022

Developments

Altamira completes patient enrollment in house dust mite allergy trial with Bentrio

Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment with its Bentrio nasal spray in a house dust mite allergic rhinitis trial and expects to release top-line results from the trial during the second quarter...

March 15, 2022

Developments

Profound Medical CEO adds to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) chairman and CEO, Arun Menawat, acquired a total of 60,599 shares of Profound on the open market at a cost of $497,180 (U.S.). According to a filing with SEDI, Dr. Menawat...

March 11, 2022

Developments

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

March 11, 2022

Developments

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Altamira Therapeutics’ (NASDAQ:CYTO) affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of its Bentrio nasal spray in COVID-19 patients. The COVAMID study is a...

March 9, 2022

Developments

Cannabotech technology eliminated 90%-plus of colon cancer cells in cell model

Closely-held Cannabotech of Israel reports that its cell model study results have shown that its integrative colon products killed more than 90% of colon cancer cells in a cell model experiment. The integrative colon...

March 7, 2022

Developments

Altamira, Nuance in pact to distribute Bentrio in China, other Asian markets

Altamira Therapeutics (NASDAQ:CYTO) entered into an exclusive licensing and distribution agreement with Nuance Pharma for Altamira’s Bentrio nasal spray for protection against airborne viruses and allergens in the...

March 4, 2022

Category - Developments

Subscribe